Scientific and research AI for life sciences, built on what your organization actually knows rather than on what the field chose to publish.
Mining the published literature at scale is the obvious first application of AI in research and it carries a problem that scale makes worse rather than better. The published record is a filtered sample: experiments that produced a signal, in systems where the signal appeared, written up by people with a reason to write them up. The experiments that failed are largely absent, the ones that failed quietly are entirely absent, and a meaningful proportion of what did get published does not replicate. A model reading fifty thousand papers does not average that bias away, because the bias is systematic rather than random. It learns the shape of the published record with great fidelity and reports it back with confidence.
Every research organization holds a body of evidence that nobody outside it has: the compounds that failed, the targets that did not validate, the assays that behaved unexpectedly, the conditions under which something stopped working, the hypotheses that were tested and abandoned. This is genuine, expensively acquired scientific information and it is almost never treated as data. It exists as entries in electronic notebooks nobody has read since, as presentations in shared drives, as results in instrument files with no context attached, and increasingly as nothing at all because the person who ran the experiment has left.
The consequence is twofold and both halves are expensive. The organization repeats work it has already done, sometimes several times across sites and years, because there is no way to discover that it was done. And when it builds models on literature, it builds them on a dataset biased toward success while holding the counter-examples that would have corrected it. The asymmetry is substantial: every competitor has access to the same publications, and nobody else has your failures. Making that body of evidence findable and usable is unglamorous data engineering, it is slow, and it is the single highest-value thing most research organizations could do with AI.
Published evidence is filtered toward positive results
And scale amplifies that bias rather than averaging it, because the bias is systematic.
Internal negative results are unstructured and unindexed
The most differentiating data in the organization is also the least accessible.
Experimental context lives outside the record
The conditions, the deviations and the judgement that explain a result were never written down.
The same work gets repeated across sites and years
Not through carelessness, but because discovering prior work is harder than redoing it.
Analyses cannot be re-run
Environment, versions, parameters and data as it stood are rarely captured together.
Hypotheses are abundant and experiments are scarce
Generation is not the bottleneck, and tools that generate more of them do not help.
Ask how often you have already run the experiment somebody is proposing. Take three recently approved experimental plans and try to establish, from your own records, whether anything closely comparable has been done before in your organization. Not whether somebody remembers, but whether it can be found. In most research organizations this cannot be answered at all, which means the rate of duplicated work is unknown and therefore unmanaged. That exercise usually does more to justify a research data programme than any projection of discovery acceleration, because it measures something real and the answer is uncomfortable.
We are data and AI engineers working alongside your scientists, who own the science. The sequence below reflects that division: the work we can do well is making your evidence findable, structured, linked and reproducible, which is what then makes any model built on it worth trusting.
Step 1
Start from the decisions, not the data
Step 2
Inventory the internal evidence
Step 3
Capture the negative and the abandoned
Step 4
Structure the entities and their relationships
Step 5
Preserve experimental context with the result
Step 6
Establish computational reproducibility
Step 7
Build retrieval across internal and external evidence together
Step 8
Apply modelling where the data supports it
Step 9
Design scientific review into the output
Step 10
Validate against held-out reality
The first useful system is usually search, and nobody finds that exciting. Before any model, most research organizations would gain more from being able to answer a simple question: has anyone here worked on this, and what did they find. That requires internal results to be indexed, linked to the entities they concern, and retrievable by scientists who were not involved, which is data engineering rather than machine learning. It is also the foundation every subsequent model depends on, since a model built on evidence the organization cannot locate is a model built on a subset chosen by accident.
Three groups in the order they produce value. We build all three and we are explicit that the first one determines the ceiling on the other two.
Research evidence engineering
Internal results made findable
notebooks, instrument output, reports and presentations, indexed and linked
Deliberate capture of negative and abandoned results, which no normal workflow preserves
Entity resolution across compounds, targets, assays, samples, subjects and conditions
Experimental context preserved with the result, including protocol version and recorded deviations
Knowledge graph construction where relationship questions are the questions being asked
Computational provenance
environment, code version, parameters, data version and seed, captured at run time
Modelling and analysis
Predictive modelling on research data where the sample size and design support it, and a clear answer where they do not
Machine learning for screening prioritisation, property prediction and pattern identification across assays
Multi-modal integration across omics, imaging, assay and clinical data, with the batch effects addressed rather than ignored
Uncertainty quantification and applicability domain, so a prediction states where it does not apply
Experimental design support, including power and the question of what the proposed study can actually detect
Pipeline engineering for reproducible analysis at scale, including HPC and cloud compute where the work requires it
Scientific assistance
Literature intelligence across external publications and internal reports in one retrieval surface
Scientific NLP for entity extraction, relationship identification and terminology normalisation
Research assistants grounded in retrievable sources, built to decline rather than to synthesise
Evidence strength marked on every assertion
established finding, preliminary result, computational prediction or inference
Systematic review and evidence synthesis support, with the screening work automated and the judgement left alone
Candidate prioritisation against what the organization already knows, including its own prior failures
Explanation and traceability, so a scientist can follow any output back to the evidence behind it
The third column is the honest assessment of what the available data can carry, which is the column most vendors in this category leave out. Scoping from it produces work that survives contact with a scientific reviewer.
| Setting | What people want from AI | What the data usually supports |
|---|---|---|
| Target identification | Novel targets from evidence synthesis | Prioritisation across known candidates using internal plus published evidence |
| Screening and lead work | Property and activity prediction | Genuinely strong, where assay data is plentiful and consistently generated |
| Biomarker discovery | Signatures predicting response | Hypothesis generation needing prospective confirmation, and small n is the limit |
| Translational research | Bridging preclinical to clinical | Integration and retrieval. Prediction across that gap remains hard and should be said |
| Preclinical studies | Faster, fewer, better-designed studies | Design support, prior-work retrieval and reproducible analysis |
| Laboratory operations | Throughput and consistency | Strong and undersold: scheduling, anomaly detection, instrument data handling |
| Knowledge management | Finding what the organization knows | The highest-certainty value in the list and the least discussed |
Models change every few months and the research data layer, if it is built properly, serves a decade. That is where the durable value sits and where the effort should go, because every model the organization will build in the next ten years depends on evidence being findable, linked, contextualised and reproducible.
| Source | What it holds | Why it resists use |
|---|---|---|
| ELN | Experimental record, intent, observation, interpretation | Free text by design, and the context is in prose rather than fields |
| LIMS | Samples, tests, results, chain of custody | Structured and narrow, with the scientific meaning held elsewhere |
| Instrument output | Raw and processed measurement | Vendor formats, large files, and the metadata often stripped on export |
| Omics and imaging | High-dimensional measurement | Volume, processing-pipeline dependence and severe batch effects |
| Reports and presentations | Conclusions and the reasoning behind them | Where the actual knowledge is, and entirely unindexed |
| Published literature | The external evidence base | Access terms, formats, and the publication bias discussed throughout |
| Public databases | Reference and annotation | Versioned externally, so an analysis is tied to a release nobody records |
Retrospective performance is not evidence of anything. A model trained and evaluated on data from completed work will perform well, because the relationship it learned was present in the data that defined it. That number tells you the method can fit your historical data and it says very little about what will happen on the next series, the next cohort or the next assay campaign. The evidence a scientific organization should want is prospective: the model made a prediction before the experiment was run, the experiment was run, and the prediction was right or wrong. That takes longer, it is the only thing that convinces a scientific reviewer, and a partner unwilling to be measured that way is telling you something.
Worth stating directly because it affects cost and pace. A great deal of early research sits outside the good practice frameworks, and applying regulated controls uniformly across discovery slows work that nothing required to be slowed. The opposite error is equally common and more serious: research that will support a submission, or that generates data a regulator will examine, is held to discovery standards until somebody discovers late that the provenance is not there. Which of your work falls where is a determination for your quality and regulatory functions, and it needs making early because retrofitting provenance is usually impossible.
Frameworks where they apply
- GxP and GAMP 5 where research activity sits inside a regulated process, which is a smaller subset than uniform application assumes
- ICH GCP for clinical research activity, with the sponsor obligations that implies
- 21 CFR Part 11 and EU Annex 11 where records and signatures fall within scope
- ALCOA+ applied to research records that will support a regulatory position, whether or not the work was framed that way
Scientific integrity, beyond compliance
- Provenance from a result back to the raw data, the pipeline version and the parameters that produced it
- Reproducibility as an engineering property rather than an aspiration in a methods section
- Preservation of negative and abandoned results, which is a scientific obligation as much as a commercial opportunity
- Honest reporting of uncertainty, applicability domain and what a model was not trained to do
Intellectual property
- Which research content may be processed by an external model provider, under what terms on training and retention
- Pre-publication, patent-relevant and partner-confidential material treated as classes with their own handling
- Inventorship and provenance where AI contributed to something that may become patentable, which your counsel determines
- Records sufficient to evidence conception and reduction to practice, which AI involvement complicates rather than removes
Privacy
- Human subject data in translational and clinical research, with consent scope governing secondary use
- Genomic data, which is identifying in ways that ordinary de-identification does not address
- HIPAA and GDPR obligations as your counsel determines them, including for processing by a provider
- Data residency and transfer controls across multi-site and collaborative research
A wrong answer in most enterprise applications costs rework. A wrong answer in research costs a programme: months of capacity, material that cannot be recovered, and occasionally a strategic decision taken on a finding that was never there. That asymmetry is why the controls below are worth more here than their cost suggests.
| Failure | How it presents |
|---|---|
| The model learned the batch, not the biology | Excellent held-out performance that evaporates on independently generated material |
| A fabricated mechanism reads as literature | Fluent, correctly worded, cites nothing that supports it, and directs an experiment |
| A correlation is reported as a mechanism | Statistically real, causally unestablished, and presented in language that implies otherwise |
| A gene or entity name is mapped wrongly | An alias, a species difference or an ambiguous symbol attaches evidence to the wrong thing |
| Missing data is not missing at random | The absent measurements carry information and the model inherits the bias in their absence |
| A model update changes a prior conclusion | A result the organization already acted on no longer reproduces and nobody reassessed it |
| A signature found in small n does not replicate | Real in the discovery cohort, absent in validation, and the statistics predicted it |
| Leakage between training and evaluation | Related samples split across both sides, so the model was partly tested on its training data |
| A public database release changed | An annotation moved and the analysis now says something different with no code change |
| Prediction applied outside its domain | The chemistry or cohort sits outside what the model saw, and nothing in the output says so |
| An analysis cannot be reproduced | The result stands, the path to it does not, and the decision rests on it |
| Negative evidence is absent from the input | The model saw only what worked, and recommends what the field already tried and abandoned |
Scientific AI programmes get reported as models deployed and papers screened. The outcomes a research organization should hold a partner to are whether decisions improved, whether work stopped being repeated, and whether anything the system predicted turned out to be true in an experiment nobody had run yet.
| Category | What we measure | Why it matters |
|---|---|---|
| Prospective prediction accuracy | Predictions made before the experiment, checked after it | The only accuracy figure a scientific reviewer will accept |
| Internal evidence retrievability | Share of prior internal work findable by someone not involved | The foundation everything else depends on, and the cheapest to improve |
| Duplicated work detected | Proposed experiments found to have close internal precedent | Direct, measurable saving, and usually a surprising number |
| Negative results captured | Failed and abandoned work entering the evidence base | The differentiating asset, and it only accumulates deliberately |
| Analyses reproducible on demand | Proportion re-runnable from recorded provenance | Distinguishes a result from a figure somebody once produced |
| Decision influence | Research decisions where the system changed what was done | Usage without influence is a tool nobody is really using |
| Screening and triage effort | Scientist hours on literature and data preparation | The clearest near-term saving, and it is large |
We will start from the decisions rather than the data, make your internal evidence findable including the parts that did not work, establish reproducibility as an engineering property, and apply modelling where the data supports it while telling you plainly where it does not.
CaliberFocus is a life sciences AI partner delivering scientific and research AI built on what your organization actually knows, not only on what the field chose to publish. From making internal evidence findable, including the experiments that did not work, to reproducible analysis pipelines, careful modelling and research assistants grounded in retrievable sources, we work alongside your scientists and say plainly where the data will not support a claim.
- Internal and negative results made findable and usable
- Reproducibility engineered in from the start
- Models judged against baselines and prospective results
- Scientific review and judgement stay with your scientists
Security & Compliance
